Abstract: The compound and pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth.
Abstract: Provided herein are methods of purifying messenger RNA (mRNA) by subjecting a preparation comprising in vitro synthesized mRNA to one or more steps of enzymatic digestion with a proteinase, optionally with a further oligo dT affinity chromatography step. Also provided are mRNA purified by the methods described herein.
Type:
Grant
Filed:
July 28, 2023
Date of Patent:
October 29, 2024
Assignee:
SANOFI
Inventors:
Eric Calvosa, Nicolas Chaudet, Arthur Leclercq, Alban Lepetitcolin
Abstract: The disclosure describes compounds of Formula Ia, which in non-limiting aspects contain an asialoglycoprotein receptor (ASGPR) binding moiety and an anti-?1AR binding moiety. Compounds of Formula Ia are useful in preventing, treating, and/or ameliorating heart failure in a subject when administered in therapeutically effective amounts.
Type:
Grant
Filed:
March 8, 2023
Date of Patent:
October 29, 2024
Assignee:
Yale University
Inventors:
David Caianiello, Edward Deramon, David Spiegel
Abstract: In one aspect, the invention relates to an immunogenic composition comprising modified O-polysaccharide molecules derived from E. coli lipopolysaccharides and conjugates thereof. Multivalent vaccines may be prepared by combining two or more monovalent immunogenic compositions for different E. coli serotypes. In one embodiment, the modified O-polysaccharide molecules are produced by a recombinant bacterium that includes a wzz gene.
Type:
Grant
Filed:
February 15, 2022
Date of Patent:
October 29, 2024
Assignee:
Pfizer Inc.
Inventors:
Robert G. K. Donald, Annaliesa Sybil Anderson, Laurent Oliver Chorro, Jianxin Gu, Jin-Hwan Kim, Srinivas Kodali, Jason Arnold Lotvin, Justin Keith Moran, Rosalind Pan, Avvari Krishna Prasad, Mark Edward Ruppen, Suddham Singh, Ling Chu, Scott Ellis Lomberk, Karen Kiyoko Takane, Nishith Merchant, Wei Chen
Abstract: The disclosure provides a topical gel formulation comprising 1-1.5 wt. % clindamycin phosphate, 2.5-3.5 wt. % benzoyl peroxide, and 0.1-0.2 wt. % adapalene, in combination with a gelling agent, a polyhydric alcohol, and water, useful in treating inflammatory skin conditions, including acne, together with methods of making and using the same.
Abstract: A food supplement is disclosed that comprises an extracellular matrix composition of hydrolyzed collagen, hyaluronic acid and glucosamine, ascorbic acid and, optionally, a cannabinoid composition. The food supplement can be given to pet animals for the relief of or prophylaxis of degenerative joint diseases, such as arthritis.
Abstract: Dispersion type feed additive compositions for ruminants, containing (A) at least one selected from hydrogenated vegetable oil and hydrogenated animal oil each having a melting point of higher than 50° C. and lower than 90° C., (B) not less than 0.01 wt % and not more than 6 wt % of a surfactant, (C) not less than 16 wt % and not more than 72 wt % of a biologically active substance (excluding L-lysine and a salt thereof), and (D) not less than 1 wt % and not more than 40 wt % of L-lysine or a salt thereof, contain a biologically active substance at a high concentration, show high protection in the rumen, and are also superior in dissolution in the intestinal tract.
Type:
Grant
Filed:
December 29, 2022
Date of Patent:
October 22, 2024
Assignee:
AJINOMOTO CO., INC.
Inventors:
Sachiko Yonemaru, Koji Haga, Yuki Miyazawa, Susumu Shibahara
Abstract: The disclosure is directed to ABC294640, as free base or as salts thereof, in preparing medicines for treating coronavirus infection or preventing diseases caused by coronavirus infection, and a medicine for preventing coronavirus infection or preventing diseases caused by coronavirus infection.
Type:
Grant
Filed:
August 31, 2022
Date of Patent:
October 15, 2024
Assignee:
RedHill Biopharma Ltd.
Inventors:
Dror Ben-Asher, Reza Fathi, Mark Levitt, Ofra Barnett
Abstract: Disclosed herein are acylated active agents and methods of their use, e.g., for modulating an autoimmunity marker or for treating an autoimmune disorder.
Type:
Grant
Filed:
December 21, 2021
Date of Patent:
October 15, 2024
Assignee:
Flagship Pioneering Innovations V, Inc.
Inventors:
Steven John Taylor, Mi-Jeong Kim, Kathleen Nudel, Timothy F. Briggs, Koji Yasuda, Leonard Buckbinder, Bernard Lanter, Spencer Cory Peck, Cheri Snedeker, Angela She, Jessica Alexander, Anna Liang, Jenny Liu, Dinara Gunasekera, David Arthur Berry, John Patrick Casey, Jr., Amir H. Moarefi
Abstract: Described are novel targeting ligands that may be linked to compounds, such therapeutic compounds, that are useful in directing the compounds to the target in vivo. The targeting ligands disclosed herein can serve to target expression-inhibiting oligomeric compounds, such as RNAi agents, to liver cells to modulate gene expression. The targeting ligands disclosed herein, when conjugated to an expression-inhibiting oligomeric compound, may be used in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Compositions including the targeting ligands disclosed herein when linked to expression-inhibiting oligomeric compounds are capable of mediating expression of target nucleic acid sequences in liver cells, such as hepatocytes, which may be useful in the treatment of diseases or conditions that respond to inhibition of gene expression or activity in a cell, tissue, or organism.
Type:
Grant
Filed:
February 24, 2021
Date of Patent:
October 15, 2024
Assignee:
Arrowhead Pharmaceuticals, Inc.
Inventors:
David B. Rozema, Darren H. Wakefield, Andrei V. Blokhin, Jonathan D. Benson, Zhen Li, Tao Pei, Fred Fleitz
Abstract: An enzymatically produced soluble ?-glucan fiber composition is provided suitable for use as a digestion resistant fiber in food and feed applications. The soluble ?-glucan fiber composition can be blended with one or more additional food ingredients to produce fiber-containing compositions. Methods for the production and use of compositions comprising the soluble ?-glucan fiber are also provided.
Type:
Grant
Filed:
February 25, 2022
Date of Patent:
October 8, 2024
Assignee:
NUTRITION & BIOSCIENCES USA 4, INC.
Inventors:
Qiong Cheng, Robert DiCosimo, Arthur Ouwehand, Zheng You, Mark S. Payne, Jian Ping Lai, Kristin Ruebling-Jass, Steven Cary Rothman
Abstract: The invention relates to inactivating mold spores in a beverage using pasteurization in the presence of natamycin and to a beverage comprising natamycin and mycosamine.
Abstract: The present invention discloses a method to recover and restore dendritic and synaptic neuron connections that have been degraded or destroyed by neurodegenerative diseases. In the present invention tryptamines are used to induce neuro plasticity and restore both dendritic density and synaptic connections of neurons in the brain. In the preferred embodiment LSD given in micro doses can induce dendritic and synaptic genesis in neuronal networks and improve the quality of life of people with neurodegenerative diseases such as Alzheimer's, Huntington's, Multiple Sclerosis, Parkinson's and Frontotemporal dementia.
Abstract: A pharmaceutical composition for preventing or treating eye diseases and an oral administration agent for preventing or treating eye diseases are provided, wherein the pharmaceutical composition for preventing or treating eye diseases includes the compound represented by Chemical Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient.
Type:
Grant
Filed:
August 26, 2021
Date of Patent:
September 10, 2024
Assignee:
FUTURE MEDICINE CO., LTD.
Inventors:
Sang Koo Lee, Chong Woo Park, Hea Ok Kim, Hee Woo Lee, Mi Ra Yu
Abstract: Compounds useful as biologically active compounds are disclosed. The compounds have the following structure (I): or a stereoisomer, tautomer or salt thereof, wherein A, R1, R2, R3, R4, R5, L, L1, L2, L3, L4, M, m and n are as defined herein. Methods associated with preparation and use of such compounds is also provided.
Abstract: The present invention provides a crystal of 1-{2-[(3S,4R)-1-[(3R,4R)-1-cyclopentyl-3-fluoro-4-(4-methoxyphenyl)pyrrolidine-3-carbonyl]-4-(methoxymethyl)pyrrolidin-3-yl]-5-(trifluoromethyl)phenyl}piperidine-4-carboxylic acid having a certain quality that can be used as a drug substance. Specifically, the present invention provides a crystal comprising an equimolar amount of 1-{2-[(3S,4R)-1-[(3R,4R)-1-cyclopentyl-3-fluoro-4-(4-methoxyphenyl)pyrrolidine-3-carbonyl]-4-(methoxymethyl)pyrrolidin-3-yl]-5-(trifluoromethyl)phenyl}piperidine-4-carboxylic acid and phosphoric acid.
Type:
Grant
Filed:
December 27, 2019
Date of Patent:
September 3, 2024
Assignee:
MITSUBISHI TANABE PHARMA CORPORATION
Inventors:
Naoko Ueda, Hiroomi Nagata, Takahiro Yoshida
Abstract: System for and method of producing a pure starch slurry and alcohol by using combined corn wet and dry milling processes. A simple and lower cost process to obtain starch inside floury endosperm is provided. The starch can be highly purified to meet green technology process needs. The remaining starch inside the corn kernels can be used as feedstock for alcohol production and to produce valuable co-products such as oil and various animal feeds.
Abstract: The present invention provides methods for making polysaccharide-protein conjugates in which polysaccharides, typically from bacteria, are conjugated to a carrier protein by reductive amination under conditions which improve conjugation reaction consistency, increase consumption of protein during conjugation reaction, generate conjugates of higher molecular weight, and/or reduce the levels of free cyanide in the conjugate reaction product. The polysaccharide-protein conjugates obtained using these methods are useful for inclusion in multivalent vaccines.
Type:
Grant
Filed:
November 10, 2021
Date of Patent:
August 13, 2024
Assignee:
Merck Sharp & Dohme Corp.
Inventors:
Jitin Bajaj, Michael Albert Winters, Emily Wen, Jian He
Abstract: The present invention relates to a new apparatus and a new method for the purification and the recovery of extra-chromosomal nucleic acids sequence(s).